Nektar Therapeutics (NKTR) CEO Howard Robin on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/05/21
Nektar Therapeutics (NKTR) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/04/21
Nektar to Announce Financial Results for the Third Quarter 2021 on Thursday, November 4, 2021, After Close of U.S.-Based Financial MarketsPRNewsWire • 10/26/21
Nektar Sends Shot Across Bristol Myers Squibb's Bow With Big Pfizer CollaborationSeeking Alpha • 09/23/21
Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley StudyPRNewsWire • 09/21/21
Nektar Therapeutics (NKTR) CEO Howard Robin on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/06/21
Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Based Financial MarketsPRNewsWire • 07/27/21
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare ConferencePRNewsWire • 06/07/21
Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational AutoimmunityPRNewsWire • 05/20/21
Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)PRNewsWire • 05/18/21
Nektar Therapeutics (NKTR) CEO Howard Robin on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/07/21